- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03935854
Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar or Schizophrenia Illness
Impact of A Low-Carbohydrate, High-Fat, Ketogenic Diet on Obesity, Metabolic Abnormalities and Psychiatric Symptoms in Patients With Bipolar or Schizophrenia Illness: A Pilot Trial
To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with either schizophrenia or bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or are currently taking psychotropic medications experiencing metabolic side effects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Adults with mental illness represent a high-risk, marginalized group in the current metabolic and obesity epidemic. Among US adults with severe mental illness, metabolic syndrome are highly prevalent conditions having severe consequences, with patients estimated to die on average 25 years earlier than the general population largely of premature cardiovascular disease. Many psychiatric medications, particularly neuroleptics and mood stabilizers, may, in addition, contribute to metabolic side effects and weight gain. Low-carbohydrate high-fat (LCHF) or ketogenic diets (KD) have been shown to reduce cardiovascular risk in those with insulin resistance. Recent findings support the idea that bipolar disorder, along with other psychiatric diseases schizophrenia, may have roots of metabolic dysfunction: cerebral glucose hypometabolism, oxidative stress, as well as mitochondrial and neurotransmitter dysfunction which has downstream effects on synapse connections. A KD diet provides alternative fuel to the brain aside from glucose and is believed to contain beneficial neuroprotective effects, including stabilization of brain networks, reduction of inflammation and oxidative stress. The purpose of this study is to evaluate both the metabolic and psychiatric outcomes with a KD diet in this psychiatric population.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University Department of Psychiatry & Behavioral Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-75 years old
- Meet DSM V criteria for schizophrenia or bipolar disorder, any subtype, for > 1 year and clinically stable (with no hospitalization for past 3 months)
- Currently taking psychotropic medication and gained at least 5% weight since starting medication or have a BMI greater than or equal to 26 kg/m2 or presence of at least one metabolic abnormality (hypertriglyceridemia, insulin resistance, dyslipidemia, impaired glucose tolerance)
- Willing to consent to all study procedures and attend follow-up appointments and motivated to follow the dietary program.
- Sufficient control over their food intake to adhere to study diets.
- Willingness to regularly monitor blood pressure, glucose, dietary intake, and body weight over the 4-month trial
Exclusion Criteria:
-
Any subject pregnant or nursing
-
Comorbidity of developmental delay
-
Active substance abuse with illicit drugs or alcohol
-
In a current severe mood or psychotic state when entering the study that would prohibit compliance with study visits or dietary program.
-
Anyone who has been hospitalized or taken clozapine over the past 3 months
-
Inability to complete baseline measurements
-
Severe renal or hepatic insufficiency
-
Cardiovascular dysfunction, including diagnosis of:
- Congestive heart failure
- Angina
- Arrhythmias
- Cardiomyopathy
- Valvular heart disease
-
Any other medical condition that may make either diet dangerous as determined by the study medical team (e.g. anorexia nervosa)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Ketogenic Diet 16 Week Group
Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support |
Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in heart rate from baseline
Time Frame: Baseline, 16 weeks
|
Heart rate recorded at 9 visits during study |
Baseline, 16 weeks
|
|
Change in blood pressure from baseline
Time Frame: Baseline, 16 weeks
|
Blood pressure recorded at 9 visits during study |
Baseline, 16 weeks
|
|
Change in weight from baseline
Time Frame: Baseline, 16 weeks
|
Weight recorded at 9 visits during study |
Baseline, 16 weeks
|
|
Change in waist circumference from baseline
Time Frame: Baseline, 16 weeks
|
waist circumference measured at 9 visits during study |
Baseline, 16 weeks
|
|
Change in visceral fat mass from baseline
Time Frame: Baseline, 16 weeks
|
Body composition (SECA) recorded at 5 visits during study |
Baseline, 16 weeks
|
|
Change in body fat mass from baseline
Time Frame: Baseline, 16 weeks
|
Body composition (SECA) recorded at 5 visits during study |
Baseline, 16 weeks
|
|
Percent Change in Hemoglobin A1c from baseline
Time Frame: Baseline, 16 weeks
|
Hemoglobin A1c recorded at initial and final visits |
Baseline, 16 weeks
|
|
Change in insulin resistance measure (HOMA-IR) from baseline
Time Frame: Baseline, 16 weeks
|
HOMA-IR measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in inflammatory marker (hsCRP) from baseline
Time Frame: Baseline, 16 weeks
|
hsCRP measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in lipid profile TG (triglycerides) from baseline
Time Frame: Baseline, 16 weeks
|
Lipid profile TG measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in lipid profile small LDL (small dense LDL) from baseline
Time Frame: Baseline, 16 weeks
|
Lipid profile small LDL measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in lipid profile (HDL) from baseline
Time Frame: Baseline,16 weeks
|
Lipid profile HDL measured at initial and final visits |
Baseline,16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psychiatric Indices - Mood
Time Frame: Baseline, 16 weeks
|
Change in Mood Qualitative Score (Clinical Mood Monitoring) from baseline |
Baseline, 16 weeks
|
|
Psychiatric Indices- Clinical Global Impression
Time Frame: Baseline, 16 weeks
|
Change in Clinical Global Impression Scales (CGI) from baseline 1-7 scale. 1= not at all ill, 7= among the most extremely ill patients) |
Baseline, 16 weeks
|
|
Generalized Anxiety Disorder - GAD-7 Anxiety
Time Frame: Baseline, 16 weeks
|
Change in Generalized Anxiety Symptom (GAD-7) scale from baseline. 0-15+ scale. (0= no anxiety, 15+= severe anxiety) |
Baseline, 16 weeks
|
|
Patient Health Questionnaire - PHQ-9 Depression
Time Frame: Baseline, 16 weeks
|
Change in Patient Health Questionnaire (PHQ-9) from baseline. Score range 0-27 (0= no depression, 27= severe depression) |
Baseline, 16 weeks
|
|
Psychiatric Indices- Global Assessment of Functioning
Time Frame: Baseline, 16 weeks
|
Change in Global Assessment of Functioning (GAF) Scale from baseline. 1-100 scale (1= persistent danger of hurting self or others, 100= superior functioning) |
Baseline, 16 weeks
|
|
Psychiatric Indices- Quality of Life
Time Frame: Baseline, 16 weeks
|
Change in Manchester Quality of Life Scale (MANSA) from baseline. Range 12-84 (each of 12 outcomes rated from 1= could not be worse to 7= could not be better; <4= dissatisfied with QoL, >4= satisfied with QoL) |
Baseline, 16 weeks
|
|
Psychiatric Indices- BPRS
Time Frame: Baseline, 16 weeks
|
Change in Brief Psychiatric Rating Scale (BPRS) from baseline. Score range 18-126. (For each of 18 symptoms, 1=symptom not present, 7= extremely severe) |
Baseline, 16 weeks
|
|
Pittsburgh Sleep Quality Index - PSQI
Time Frame: Baseline, 16 weeks
|
Change in Pittsburgh Sleep Quality Index from baseline. 0-21 scale (<5=good sleeper; 5+= meaningfully disturbed sleep or poor sleeper) |
Baseline, 16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shebani Sethi, MD, Stanford University
Publications and helpful links
General Publications
- Yu B, Ozveren R, Sethi Dalai S. Ketogenic diet as a metabolic therapy for bipolar disorder: Clinical developments. Submitted to Journal of Affective Disorders. Research Square preprint March 2020: DOI is: 10.21203/rs.3.rs-334453/v1
- Sarnyai Z, Kraeuter AK, Palmer CM. Ketogenic diet for schizophrenia: clinical implication. Curr Opin Psychiatry. 2019 Sep;32(5):394-401. doi: 10.1097/YCO.0000000000000535.
- Brietzke E, Mansur RB, Subramaniapillai M, Balanza-Martinez V, Vinberg M, Gonzalez-Pinto A, Rosenblat JD, Ho R, McIntyre RS. Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neurosci Biobehav Rev. 2018 Nov;94:11-16. doi: 10.1016/j.neubiorev.2018.07.020. Epub 2018 Jul 31.
- Norwitz NG, Sethi S, Palmer CM. Ketogenic diet as a metabolic treatment for mental illness. Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):269-274. doi: 10.1097/MED.0000000000000564.
- Sethi S, Sinha A, Gearhardt AN. Low carbohydrate ketogenic therapy as a metabolic treatment for binge eating and ultraprocessed food addiction. Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):275-282. doi: 10.1097/MED.0000000000000571.
- Sethi S, Wakeham D, Ketter T, Hooshmand F, Bjornstad J, Richards B, Westman E, Krauss RM, Saslow L. Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial. Psychiatry Res. 2024 May;335:115866. doi: 10.1016/j.psychres.2024.115866. Epub 2024 Mar 20.
- Carmen M, Safer DL, Saslow LR, Kalayjian T, Mason AE, Westman EC, Sethi S. Treating binge eating and food addiction symptoms with low-carbohydrate Ketogenic diets: a case series. J Eat Disord. 2020 Jan 29;8:2. doi: 10.1186/s40337-020-0278-7. eCollection 2020.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bipolar and Related Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Schizophrenia Spectrum and Other Psychotic Disorders
- Mental Disorders
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Body Weight Changes
- Glucose Metabolism Disorders
- Mood Disorders
- Insulin Resistance
- Hyperinsulinism
- Overweight
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Schizophrenia
- Obesity
- Bipolar Disorder
- Metabolic Syndrome
- Weight Gain
- Brain Diseases, Metabolic
- Therapeutics
- Diet, Food, and Nutrition
- Physiological Phenomena
- Nutritional Physiological Phenomena
- Diet Therapy
- Nutrition Therapy
- Diet
- Diet, Carbohydrate-Restricted
- Diet, Ketogenic
Other Study ID Numbers
- 48527
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.